Company profile: CTI Science
1.1 - Company Overview
Company description
- Provider of biotechnology research and development focused on improving human and animal health, developing a flagship product for submission for regulatory drug approval. Founded in 2007 by Dr. Boyd E. Haley, based in Lexington, Kentucky, United States.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CTI Science
TargeGen
HQ: United States
Website
- Description: Provider of vascular biology-focused small molecule kinase inhibitors targeting vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation, offering treatments for human diseases such as heart attack, cancer, and eye diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TargeGen company profile →
Chronos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of age-related disease drug development, advancing SFX-01, a sulforaphane-based stable tablet for oncology and neurodevelopmental disorders; a highly selective orexin 1 receptor antagonist for addictive behaviors including binge eating disorder and alcohol use disorder; and an atypical DAT inhibitor for fatigue and narcolepsy, plus licensing and partnership collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chronos Therapeutics company profile →
Innate Pharma
HQ: France
Website
- Description: Provider of first-in-class immunotherapy drug candidates for cancer and inflammatory diseases, specializing in novel monoclonal antibodies and NK cell engagers targeting innate immunity pathways. Pipeline includes ANKET; Lacutamab for cutaneous and peripheral T cell lymphomas; Monalizumab (anti-NKG2A) and CD39 with AstraZeneca for NSCLC and other solid tumors; CD123 and B7-H3 multi-specific ANKETs with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innate Pharma company profile →
Paion
HQ: Germany
Website
- Description: Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paion company profile →
Palatin Technologies
HQ: United States
Website
- Description: Provider of targeted receptor-specific peptide therapeutics, including Vyleesi (bremelanotide injection) for premenopausal women with HSDD, and a pipeline of melanocortin-based candidates: PL9643 (Phase 3) for dry eye disease; PL9654 for ocular diseases (IVT and topical); PL8177 (oral, Phase 2) for ulcerative colitis; bremelanotide + PDE5i (Phase 2) for sexual dysfunction; and a planned MCR4 agonist program for obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palatin Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CTI Science
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CTI Science
2.2 - Growth funds investing in similar companies to CTI Science
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CTI Science
4.2 - Public trading comparable groups for CTI Science
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →